stockrow
Friday 6 November 2026
Export AQST’s income statement to Excel — free account
Aquestive Therapeutics, Inc.
AQST Healthcare Drug Manufacturers Specialty & Generic
Aquestive Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.5 million, down 22.6% from fiscal 2024.
- Revenue
- −41.0%
- EPS
- +6.14%
- Free cash flow
- +40.8%
- Total debt
- +69.5%
Quarter to September 2026, against a year earlier
3.58
0.08
−2.19%
Follow AQST
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
15.51 | 10.12 | 9.61 | 11.90 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(81.56) | (34.37) | (55.08) | (82.50) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
13.40 | 8.42 | 8.73 | 11.09 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(11.39) | (9.65) | (10.41) | (13.62) | |
EV/FCF |
(11.27) | (9.55) | (10.28) | (13.31) | |
Quick Ratio |
2.92 | 3.70 | 6.54 | 5.53 | |
Current Ratio |
3.14 | 4.10 | 7.19 | 6.12 | |
Net Debt/EBITDA |
3.61 | 47.44 | 7.57 | 3.05 | |
Debt/Assets |
17.15% | 17.78% | 38.34% | 42.54% | |
Debt/Equity |
(0.82) | (0.74) | (0.90) | (0.72) | |
Asset Turnover |
0.34 | 0.41 | 0.48 | 0.35 | |
Operating CF/Net income |
0.27 | 1.84 | 0.41 | 0.43 | |
Capex/Depreciation |
(0.03) | (0.02) | (0.11) | (0.40) | |
Interest Coverage |
(6.75) | (1.07) | (2.14) | (5.02) | |
Research and Development Expense of Revenue |
24.56% | 29.10% | 28.67% | 56.25% | |
Selling, General and Administrative Expense of Revenue |
252.19% | 75.99% | 101.77% | 187.50% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
10.57% | 16.05% | 20.95% | 28.13% | |
Graham Net Nets |
(0.06) | (0.09) | (0.13) | (0.15) | |
Graham Number |
2.35 | 1.95 | 2.57 | 2.85 | |
Earnings Yield |
(12.07%) | (14.70%) | (15.63%) | (13.85%) | |
Free Cash Flow Yield |
(7.67%) | (8.71%) | (8.84%) | (7.00%) | |
Revenue per Share |
0.12 | 0.12 | 0.11 | 0.06 | |
Operating CF per Share |
(0.08) | (0.12) | (0.08) | (0.06) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.08) | (0.12) | (0.08) | (0.06) | |
Cash per Share |
1.13 | 0.90 | 0.79 | 0.72 | |
Shareholders Equity per Share |
(0.31) | (0.28) | (0.45) | (0.56) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.31) | (0.28) | (0.45) | (0.56) | |
Free Cash Flow |
(8.55) | (14.86) | (9.65) | (7.63) | |
Working Capital |
101.66 | 98.43 | 102.02 | 88.53 | |
Capital Expenditures |
(0.08) | (0.05) | (0.21) | (0.58) | |
Net Current Asset Value |
(44.82) | (45.00) | (70.20) | (84.33) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.02 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
12.55 | 8.66 | 10.60 | 8.53 | |
Average Payables |
20.07 | 12.08 | 10.46 | 9.84 | |
Average Inventory |
6.11 | 7.63 | 7.75 | 7.60 | |
Average Assets |
130.92 | 121.68 | 112.90 | 141.44 | |
Average Common Equity |
(46.91) | (47.49) | (64.59) | (37.47) |
Columns are period end dates · fundamentals updated 5 Nov 2026